ProQR Therapeutics N.V. (PRQR)

NASDAQ: PRQR · IEX Real-Time Price · USD
0.00 (0.00%)
Sep 29, 2023, 10:42 AM EDT - Market open

Company Description

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines.

The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline.

In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.

The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics N.V.
ProQR Therapeutics logo
Country Netherlands
Founded 2012
IPO Date Sep 18, 2014
Industry Biotechnology
Sector Healthcare
Employees 130
CEO Daniel Anton de Boer

Contact Details

Zernikedreef 9
Leiden, P7 2333 CK
Phone 31 88 166 7000

Stock Details

Ticker Symbol PRQR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
CIK Code 0001612940
CUSIP Number N71542109
ISIN Number NL0010872495
SIC Code 2834

Key Executives

Name Position
Dr. Domenico Valerio Ph.D. Founder and Independent Chairman of Supervisory Board
Daniel Anton de Boer Founder, Chief Executive Officer and Member of Management Board
Dr. Gerard Platenburg Co-Founder and Chief Scientific Officer
Jurriaan Dekkers Chief Financial Officer
Rene K. Beukema Chief Corporate Development Officer, General Counsel and Member of Management Board
Sheila Sponselee Vice President and Head of People and Operations
Sarah Cue Kiely Vice President of Investor Relations and Corporate Communications
Bart Klein Senior Vice President of Intellectual Property
Aniz Girach M.D. Chief Medical Officer
Sandra van der Kolk Jr. Financial Controller

Latest SEC Filings

Date Type Title
Sep 27, 2023 6-K Report of foreign issuer
Sep 14, 2023 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 3, 2023 6-K Report of foreign issuer
Aug 1, 2023 6-K Report of foreign issuer
May 17, 2023 6-K Report of foreign issuer
May 16, 2023 6-K Report of foreign issuer
Apr 24, 2023 EFFECT Notice of Effectiveness
Apr 24, 2023 424B5 Filing
Apr 18, 2023 6-K Report of foreign issuer
Mar 29, 2023 RW Filing